Tags : Agilent Technologies

M&A

Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities

Shots: ACEA to receive $250M in upfront cash as a total deal value, adding a differentiated portfolio and organizational capabilities in cell analysis Agilent will get hold of ACEA’s CFDA and CE-IVD labelled cytometer configuration, i.e. NovoCyte flow cytometer and xCELLigence Real-Time Cell analyzer used for monitoring growth, function, and cellular responses of cells The […]Read More